Dillan DiNardo - CEO of Mindstate Design Labs | Creating Novel Psychoactive Drugs at Y Combinator

Dillan DiNardo - CEO of Mindstate Design Labs | Creating Novel Psychoactive Drugs at Y Combinator

Dillan DiNardo is the CEO of Mindstate Design Labs - a preclinical-stage biotechnology company developing the next generation of psychedelic-inspired therapeutics for intractable mental health conditions.


Mindstate's mission is to map the biological basis of the varieties of psychedelic experience, and to use that map to pharmacologically design therapeutic states of mind to be applied in medically supervised settings to heal the root causes of mental health disorders. Mindstate participated in Y Combinator in 2021.



Check out Mindstate @ https://www.mindstate.design/

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(33)

Dave Messina - YC founder turned investor talks TechBio

Dave Messina - YC founder turned investor talks TechBio

Ever wondered what Pioneer Fund’s Future of Health Fund is excited about? Want to know how to impress Dave Messina? Are you curious about how different funds communicate and interact?Give a listen to ...

6 Juli 1h 16min

$HIMS Q2 Results - our take as healthcare venture capitalists

$HIMS Q2 Results - our take as healthcare venture capitalists

Brom Rector and Sam Tabone from XEIA Venture Partners - a VC firm that invests in the future of human health, wellbeing and performance - discuss $HIMS Q2 results and the HIMS business more broadly. W...

5 Aug 20251h 24min

Investing in Psychedelic BioTech [August 2025 webinar replay]

Investing in Psychedelic BioTech [August 2025 webinar replay]

Watch the video recording on YouTube: https://youtu.be/BM6x59oMnKg?si=qF0xDvgUMvU60ctP2025 has been the start of a bull period for psychedelic medicine.​Psychedelic Biotechs like GH Research, Compass ...

30 Juli 202558min

Compass and ATAI latest news + are Psychedelics BACK in 2025?!

Compass and ATAI latest news + are Psychedelics BACK in 2025?!

The past few years have been rough for psychedelic and shroom stocks, but recent news from ATAI (and Recognify), Compass Pathways and GH Research + positive regulatory tailwinds from RFK and MAHA make...

29 Juli 202516min

Bryan Johnson's Neuralink competitor - with Kernel CEO Ryan Field

Bryan Johnson's Neuralink competitor - with Kernel CEO Ryan Field

Ryan Field is the CEO of Kernel, a brain-computer interface company founded by Bryan Johnson. Kernel is a cutting edge, non-invasive BCI that uses fNIRS to image the brain. Imagine if getting an MRI w...

22 Juli 20251h 33min

How to start a VC fund

How to start a VC fund

I interviewed Michael Huseby to learn about his life story and his new book: Fundamentals: Your Friendly Guide to Investment Funds and SyndicationsThis is a great listen for anyone interested in start...

15 Juli 20251h 20min

Beyond Neuralink - Investing in Brain Computer Interfaces [webinar replay]

Beyond Neuralink - Investing in Brain Computer Interfaces [webinar replay]

Replay of our webinar on investing in brain computer interfaces. Join our upcoming July 30th event on investing in psychedelic biotech: psybio.org

12 Juli 20251h 9min

Designing Novel Brain Drugs with Xylo Bio

Designing Novel Brain Drugs with Xylo Bio

Xylo is a biotech startup that is using computational methods to design novel brain drugs to treat mental health disorders and neurodegeneration. Many of their drug candidates are inspired by naturall...

8 Juli 20251h

Populärt inom Teknik

uppgang-och-fall
market-makers
skogsforum-podcast
rss-uppgang-och-fall
rss-laddstationen-med-elbilen-i-sverige
rss-elektrikerpodden
rss-en-ai-till-kaffet
natets-morka-sida
 och-bilen-gar-bra
bli-saker-podden
rss-veckans-ai
under-femton
hej-bruksbil
elbilsveckan
developers-mer-an-bara-kod
bosse-bildoktorn-och-hasse-p
rss-fabriken-2
garagehang
klocksnack-tillsammans-med-nymans-ur-1851
bilar-med-sladd